More stories

  • in

    Evergrande’s liquidation is a new low in China’s property crisis

    “Enough is enough,” declared a Hong Kong judge on January 29th of Evergrande, a failing Chinese property behemoth, and its two-year struggle to avoid repaying its creditors. In a landmark ruling, the court ordered a liquidation of the company, which, with more than $300bn in liabilities, is the world’s most indebted real-estate developer. A provisional liquidator will be appointed, assuming management of the company. Now foreign creditors must attempt to recoup their losses from a firm that holds most of its assets in mainland China. The ruling could pit Hong Kong’s courts against a Chinese government determined to restore public confidence to a struggling market.No firm has been more central to China’s property crisis, which kicked off when Evergrande first showed signs of weakening in mid-2021. Government rules meant to wean developers from debt eventually pushed the company to default later that year. Since then a majority of China’s listed property developers have either failed to pay their investors back or have been forced into restructuring. Their access to credit has been virtually cut off, causing builders to stop working on projects across the country. Prospective homebuyers have delayed purchases, leading to a 6.5% decline in the value of sales, year on year. This has unnerved a population that stores most of its wealth in property.Until relatively recently policymakers had hoped that a successful restructuring of Evergrande could pave the way for a slow but steady revitalisation of the market. Instead, Evergrande missed important deadlines for producing a restructuring plan and, when it did offer one, underwhelmed investors. Its proposal, which was panned by bondholders, involved giving creditors a stake in some of Evergrande’s other businesses, such as its electric-vehicle line. Far from restoring confidence, the battle became increasingly ugly. At one point a group of bondholders demanded that Hui Ka Yan, Evergrande’s chairman, put up $2bn of his own money. Mr Hui was later detained by Chinese authorities. His whereabouts are unknown.The housing crisis has drained global investors of confidence in Chinese policymaking. It is now doing similar damage to Hong Kong’s reputation. For decades, foreign investors have gained access to China through Hong Kong. One of Hong Kong’s distinct features has been a legal system, separate from China’s, that is based on common law. But court rulings in Hong Kong have no guarantee of being upheld in mainland China, where almost all of Evergrande’s assets are based.
    The liquidator appointed by a Hong Kong court will be forced to deal with local authorities that may not recognise an order drawn up outside China’s legal system. Although a pilot project to recognise cross-border rulings was set up in 2021, qualification requirements are tough and the scheme is only recognised in a few cities. Hong Kong rulings can easily be shot down by mainland courts if they have the potential to disturb public order.Indeed, as Tommy Wu of Commerzbank, a German lender, has written, a full liquidation of Evergrande’s Chinese assets would probably send a shock through the Chinese economy. Property developers have sold many properties to ordinary Chinese folk that they have not yet provided. Investors’ claims on Evergrande’s projects or any cash holdings it still has could get in the way of their delivery. This would work against Beijing’s best efforts to restore confidence in the market. Any such activity would be viewed by policymakers as unacceptable, almost guaranteeing that the liquidation process will be long and drawn out.The latest Hong Kong ruling leaves room for restructuring, with the judge noting that Evergrande can still offer this to creditors. The company says that it aims to produce a new plan, possibly by March, and since a liquidator will be taking over negotiations there may now be a better chance of a deal. But it will not be one that includes many Chinese assets. And for a firm that mainly owns Chinese property, that is a problem. Evergrande’s liquidation marks a new low in China’s property crisis—it is far from the end of it. ■ More

  • in

    FanDuel-parent Flutter to list on the NYSE, challenging DraftKings as sports-betting pure play

    FanDuel-parent Flutter lists on the New York Stock Exchange, its first U.S. listing, under the ticker symbol FLUT.
    Flutter expects to give DraftKings competition for earned media and investment capital.
    Jefferies analysts believe Flutter could get a 20% premium on DraftKings’ valuation.

    FanDuel-parent Flutter lists on the New York Stock Exchange Monday, offering U.S. investors an alternative to the biggest pure play in sports betting, DraftKings.
    It’s a secondary listing for the international sportsbook, which will retain its primary listing on the London Stock Exchange and included in the FTSE 100 index.

    But Flutter’s most important market for revenue and growth is the United States, where FanDuel is the market share leader. In the fourth quarter, FanDuel had 43% market share based on gross revenue and 51% based on net revenue.
    But while FanDuel outperforms its competitors, its biggest rival DraftKings grabs the headlines and spotlight in earned media as the biggest (some might argue, the only) publicly traded pure play in sports betting. Shares of DraftKings have soared more than 150% over the last 12 months and are up 9% year to date.
    Flutter wants some of the glory and some of the capital for FanDuel. Its shares will trade on the NYSE under the ticker symbol FLUT.
    Flutter CEO Peter Jackson put it more diplomatically on Jan. 18, saying, “The additional listing will enable us to access deeper capital markets as well as making Flutter more accessible to U.S. investors and marks a new chapter in the history of the Flutter Group.”
    Jefferies believes the NYSE listing could be a short-term catalyst for Flutter. In a note published Friday, analyst James Wheatcroft assumes a 20% premium to DraftKings’ valuation, because of FanDuel’s “sustained market share outperformance” and implies a price target of £210. Flutter is currently trading at £163 per share in London.

    While DraftKings has gathered momentum since its public listing via SPAC in April 2020, hitting an all-time intraday high of $74.38 on March 22, 2021, it has lagged FanDuel in posting profits.
    Other competitors have become profitable in certain quarters, though they have failed to gain significant market share. BetMGM, jointly owned by MGM Resorts International and Entain, has seen its market leader status in iGaming (online casino games) slip, as DraftKings and FanDuel have overtaken it.
    Caesars Sportsbook, Penn Entertainment’s newly relauched ESPN Bet and Michael Rubin’s Fanatics Sportsbook, headed up by former FanDuel CEO Matt King, are also intent on taking share from FanDuel and Draftkings.

    FanDuel CEO Amy Howe told CNBC in October at the Global Gaming Expo in Las Vegas that the company is ready to take on its well-capitalized competition.
    “We know the scale is going to matter. And we know that having the most distinctive product is going to matter,” she said.
    Flutter will delist its shares from trading on the Euronext Dublin to minimize regulatory complexity, though Flutter will remain incorporated in Ireland for tax purposes, according to the company’s website. The delisting makes it ineligible for inclusion on the Euro Stoxx 50 index. More

  • in

    Zelenskyy’s income fell drastically following Russia’s invasion, new declaration reveals

    Ukraine formally started the screening process to begin EU membership last week, and faces stringent conditions on addressing its historic corruption problem.
    The Zelenskyy family income fell almost threefold between 2021 and 2022, according to the declaration on the presidential website.

    Ukrainian President Volodymyr Zelenskyy speaks with CNBC’s Andrew Ross Sorkin at the World Economic Forum Annual Meeting in Davos, Switzerland on Jan. 16th, 2024.
    Adam Galici | CNBC

    Ukrainian President Volodymyr Zelenskyy published his income for the first time on Sunday as he looks to promote transparency and tackle corruption as part of the country’s push for EU membership.
    Ukraine formally started the screening process to begin EU membership last week and faces stringent conditions on addressing its historic corruption problem.

    The Zelenskyy family income fell almost threefold between 2021 and 2022, according to the declaration on the presidential website.
    Zelenskyy and his family members received 10.8 million Ukrainian hryvnias ($286,168) in 2021, the year before Russia invaded Ukraine, which was down almost 12 million hryvnias from the previous year. The 2021 figure included around $142,000 in income from the sale of government bonds.
    “Volodymyr Zelenskyy continues to own a number of trademarks. In particular, in 2021, the process of registering 22 trademarks, which began long before his election as President of Ukraine, was completed,” the president’s first-ever public declaration of income said.
    In 2022, the Zelenskyy family income fell to 3.7 million hryvnias due to the “temporary termination of lease agreements on the territory of Ukraine as a result of the beginning of Russia’s full-scale aggression.”
    The family’s cash balance at the end of 2022 dropped by almost 1.8 million hryvnias, the declaration said, while its asset, real estate and vehicle ownership was unchanged over the two years.

    Zelenskyy has urged all public officials to disclose their incomes as part of a wider effort to promote transparency, and Ukraine’s National Agency on Corruption Prevention last month reopened a register on declared income to public scrutiny.
    The U.S. and other allies supplying financial aid and weaponry, along with institutions such as the International Monetary Fund, have also sought assurances about Kyiv’s efforts to eradicate graft in public office.
    The Security Service of Ukraine (SBU) revealed on Saturday that it had uncovered a $40 million arms procurement corruption scheme after a two-year investigation.
    Five employees from Ukrainian arms firm Lviv Arsenal allegedly conspired with Ministry of Defense officials to embezzle funds earmarked for the purchase of 100,000 mortar shells.
    The SBU said five people had been charged and could face up to 12 years in jail if found guilty. More

  • in

    China removes state media article on plans to merge bad debt asset managers with sovereign wealth fund

    The initial plan to put China Cinda Asset Management, China Orient Asset Management and China Great Wall Asset Management under the management of China Investment Corp would reportedly happen “in the near future,” Xinhua Finance had reported Sunday.
    Beijing’s actions follow a stock market rout amid burgeoning financial risks stemming from a debt crisis in its real estate sector.

    Multi exposure of virtual abstract financial graph interface on Chinese flag and sunset sky background, financial and trading concept
    Igor Kutyaev | Istock | Getty Images

    China state media removed a story that initially reported that Beijing plans to merge its largest state-owned bad debt asset managers with China Investment Corp, one of the world’s largest sovereign fund.
    The initial report was published Sunday by Xinhua Finance.

    It cited unidentified sources as saying the plan to bring China Cinda Asset Management, China Orient Asset Management and China Great Wall Asset Management under CIC could happen “in the near future” as part of a plan to reform institutions.
    No other details were provided.
    The original story in Chinese appears to have been subsequently removed from Xinhua’s website later Monday and is no longer available online. China Investment Corp did not immediately respond to CNBC’s request for comment.
    This initial announcement, along with another by China’s securities regulator on Sunday that it’s suspending the lending of restricted shares starting Monday, underscores Beijing’s pledge last week to strengthen the “inherent stability” of its capital markets and improve market confidence.
    Beijing’s actions follow a stock market rout amid burgeoning financial risks stemming from a debt crisis in its real estate sector. Last week, China’s central bank announced its largest cut in mandatory cash reserves for banks since 2021. It also announced a fresh policy mandate aimed at easing the cash crunch for Chinese developers.

    The property market slumped after Beijing cracked down on developers’ high reliance on debt for growth in 2020, weighing on consumer growth and broader growth in the world’s second-largest economy.
    China’s real estate troubles are closely intertwined with local government finances since they typically relied on land sales to developers for a significant portion of revenue.
    — CNBC’s Evelyn Cheng contributed reporting to this story.

    This story has been updated to reflect that the original Xinhua report is no longer available online. More

  • in

    China’s luxury market is bouncing back. Analysts say these are new areas of opportunity

    LVMH results showed that despite some resumption of overseas travel, more of China’s consumers are buying luxury products at home.
    The mainland China personal luxury market grew by about 12% last year to more than 400 billion yuan ($56.43 billion), according to consulting firm Bain & Company.
    In all, about half the leading brands and several niche brands, have rebounded to 2021 sales levels, the Bain report said, without sharing specific names.

    A view of a scaled-up mock of a Louis Vuitton bag during a promotional event by the French luxury brand in Shanghai on Dec. 4, 2023.
    Future Publishing | Future Publishing | Getty Images

    BEIJING — China’s luxury sales are rebounding, and while they’re not back to 2021 levels yet, industry analysts and financial releases from major brands point to new growth opportunities versus pre-pandemic trends.
    LVMH was the latest luxury giant to announce 2023 results on Thursday, and noted that fashion and leather goods saw growth of more than 30% in China in December.

    The company’s results showed that despite some resumption of overseas travel, more of China’s consumers are buying luxury products at home.
    “Regarding the size of stores in China … there are twice as many Chinese customers as in 2019,” Bernard Arnault, chairman and CEO of LVMH, said on an earnings call, according to a FactSet transcript.
    “It means that the domestic purchase in China has grown significantly, so we have to meet that,” he said.

    The mainland China personal luxury market grew by about 12% last year to more than 400 billion yuan ($56.43 billion), according to consulting firm Bain & Company.
    While that’s still not back to 2021 levels, due to soft consumer sentiment and the resumption of some overseas luxury shopping, Bain expects the domestic luxury market to only grow in the coming years.

    Luxury purchases in mainland China accounted for about 16% of the global market last year, and is expected to reach at least 20% in 2030, said Weiwei Xing, a Hong Kong-based partner at Bain’s consumer products and retail practices in Greater China.
    “All of that data points to the importance of the Chinese luxury consumer and the China market,” she told CNBC.
    Cartier parent Richemont said earlier this month that sales in mainland China, Hong Kong and Macao grew by 25% in the three months ended Dec. 31.
    In an earnings call, the company’s CFO Burkhart Grund described the Chinese business overall as “rebuilding,” especially in the context of the prolonged real estate slump and the slow recovery of overseas tourism by Chinese shoppers.
    Consumers in China have been reluctant to spend in the last few years due to uncertainty about future income and a broad slowdown in economic growth.
    Luxury brands have increasingly turned to online channels to ensure customer engagement, said Xing from Bain. She added that companies that did well in 2023 sold luxury goods deemed investible, having iconic aspects that would last over the years.

    Niche brands and markets

    In all, about half the leading brands and several niche brands, have rebounded to 2021 sales levels, the Bain report said, without sharing specific names.
    “Niche brands that have consistently invested in building brand desirability over multiple years have experienced success,” the report said.
    As companies compete for a slice of the Chinese consumer market, one emerging segment is bedding and fine linen.
    At least four investment deals have occurred in that category in the last 18 months, according to PitchBook data. The latest transaction listed was the acquisition in August of Italian luxury bedding company Frette by investors that included Ding Shizhong, the chairman of Chinese sportswear company Anta.
    “Consumer attitudes toward bedding products are gradually changing, with more consumers willing to pay for high-quality bedding and placing greater emphasis on product quality, functionality, and additional services,” said Ashley Dudarenok, founder of ChoZan, a China marketing consultancy.

    Read more about China from CNBC Pro

    She noted that domestic home textile brands “have been actively pursuing ‘technological innovations’ and exploring the high-end bedding market to meet consumer demands.”
    However, the potential market is relatively untapped.
    While U.S. consumers account for well over 40% of the global market for high-end bed and bath textiles, Chinese consumers currently only account for about 5% or less, according to estimates from the Beijing-based consumer research institute of ZWC Partners, a venture capital firm.
    Their research found that the Chinese luxury and affordable luxury segment of the bed, bath and textile market was about $700 million large in 2023, a tiny fraction of a domestic bedding market that’s about $10 billion large. More

  • in

    Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs

    Big pharmaceutical companies like Bristol Myers Squibb, Merck and Johnson & Johnson face so-called patent cliffs that will put tens of billions of dollars in sales at risk between now and 2030.
    That refers to when patents expire for one or more leading branded products for a company, which opens up the door for competitors to sell copycats of those drugs, often at a lower price.
    Some companies appear to be well-prepared to offset some of the losses from upcoming patent expirations.

    The New York Stock Exchange welcomes Johnson & Johnson (NYSE: JNJ) to the podium. 

    Big pharmaceutical companies such as Bristol Myers Squibb, Merck and Johnson & Johnson face a looming threat that will put tens of billions of dollars in sales at risk between now and 2030, as blockbuster drugs will tumble off a so-called patent cliff.
    That refers to when a company’s patents for one or more leading branded products expire, which opens the door for competitors to sell copycats of those drugs, often at a lower price. That typically causes revenue to fall for drugmakers and costs to drop for patients, who can access more affordable options.

    Certain drugmakers appear well prepared to offset some losses from upcoming patent cliffs, as they build their drug pipelines and ink acquisitions or partnerships with other companies, some Wall Street analysts said.
    Patent cliffs are an unavoidable issue for pharmaceutical companies. They must replenish older top-selling drugs with new ones that they hope will not just sustain their sales, but also grow them.
    The loss of exclusive rights on a drug can affect companies differently, depending on how much of their sales they get from the product or what type of treatment it is. Some drugs facing patent expirations will also be subject to the Biden administration’s Medicare drug price negotiations, a policy that may further threaten the companies’ revenues. 
    The top 20 biopharma companies have $180 billion in sales at risk from patent expirations between now and 2028, according to estimates from EY.
    “It does differ by company at this stage, and I think there are a number of products in the ’25, ’30 timeframe that will be major growth drivers for large biopharma companies … but all in all, there are plenty of companies that have revenue holes to plug,” William Blair & Company analyst Matt Phipps told CNBC.

    Some top drugs set to lose exclusivity

    Merck’s Keytruda is an immunotherapy that treats melanoma, head and neck, lung and other certain types of cancers.

    Key patent expirations: 2028
    2022 sales: $20.94 billion 
    Percentage of company’s total 2022 sales: Roughly 36%
    Estimated future revenue: $14.9 billion in 2030, according to Guggenheim estimates.

    Bristol Myers Squibb’s Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke.

    Key patent expirations: 2026 to 2028
    2022 sales: $11.79 billion
    Percentage of company’s total 2022 sales: Around 25%
    Estimated future revenue: $478 million in 2032, according to Leerink Partners estimates.

    Bristol Myers Squibb’s Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. 

    Key patent expirations: 2028
    2022 sales: $8.25 billion 
    Percentage of total 2022 sales: Almost 18%
    Estimated future revenue: $3.18 billion in 2032, according to Leerink Partners estimates.

    Johnson & Johnson’s Stelara is an immunosuppressive medication used to lower inflammation and treat several conditions, including plaque psoriasis and psoriatic arthritis. 

    Key patent expirations: 2024 in Europe, 2025 in the U.S. (Stelara’s patents began to expire in the U.S. last year, but the company struck deals with competitors to delay the launches of copycat drugs).
    2022 sales: $10.86 billion
    Percentage of total 2022 sales: Around 12%
    Estimated future revenue: $2.63 billion in 2028, according to FactSet estimates.

    The type of drug matters

    Patent cliffs could differ depending on whether the product is a small-molecule drug – meaning it’s made of chemicals that have low molecular weight – or a biologic, or a medicine derived from living sources such as animals or humans.
    Many of the biggest drugs facing upcoming patent expirations are biologics, including Merck’s Keytruda, J&J’s Stelara and Bristol Myers Squibb’s Opdivo. Those drugs will inevitably rake in less revenue, but it may take time before so-called biosimilars threaten their dominance. 
    Investors will get updates on Merck and Bristol Myers Squibb’s plans for the years ahead when they report earnings on Thursday and Friday, respectively.
    Phipps said biosimilars have historically “had trouble gaining market share” from their branded counterparts. That’s unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb’s Eliquis. 
    The difference is that many biosimilars aren’t identical copies of branded biologic drugs, while generics are. 
    That means biosimilars are not interchangeable: Pharmacists can’t directly substitute a branded biologic for a biosimilar when filling a prescription. Not all patients will react to a biosimilar in the same way as they do to a biologic, which makes some physicians more wary of switching patients to them.
    Biosimilars also cost much more to research and develop, and are more complex to manufacture, than generics, making biosimilar makers less willing to sell them at significant discounts to branded counterparts, Phipps noted. 

    Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts.
    JB Reed | Bloomberg | Getty Images

    One example is AbbVie’s Humira, a biologic that helps treat an array of inflammatory diseases. Several biosimilars of Humira debuted on the market last year, but the drug has so far only lost 2% of its market share to those copycats, according to a report released this month by Samsung’s biopharmaceutical subsidiary, Bioepis. 
    That’s partly because the drugmaker has offered rebates on Humira to pharmacy benefit managers. Its lower price has cut revenue, but it is also helping the drug stay competitive.
    “What’s really impacted is not volume in the market, it’s price,” Piper Sandler senior analyst Christopher Raymond said. He added that Humira is a highly profitable drug, so AbbVie can set a lower price and “still maintain a very, very decent margin.”
    Still, AbbVie expects that Humira’s revenue declined by 35% last year compared to 2022, when the drug raked in more than $21 billion.
    Raymond forecasts a 33% drop in 2023 and an identical decline in 2024, to slash its revenue to about $9.5 billion.  

    Drugmakers prepare to offset losses

    JPMorgan sees the upcoming patent cliffs in the mid-2020s as “largely manageable” as drug pipelines improve, and expects the biopharmaceutical industry’s sales to be “roughly stable” through 2030, analyst Chris Schott said in a note in December. 
    Take Merck: Schott wrote in a January note that the company “has made substantial progress in addressing its post Keytruda” patent expiration, adding that the company’s “post 2028 profile is looking increasingly attractive.”
    During the JPMorgan Health Care Conference earlier this month, Merck CEO Robert Davis said the company expects to have more than $20 billion in sales from oncology drugs by the mid-2030s, which is double the forecast the company provided during the same time last year. 
    That improved outlook now includes three antibody-drug conjugates – which target cancer cells and minimize damage to healthy ones – from the licensing agreement Merck inked with Daiichi Sankyo in October. It also includes Merck and Moderna’s personalized cancer vaccine, which has yielded promising mid-stage data when combined with Keytruda to treat the most deadly form of skin cancer. 
    The company also hiked its revenue outlook for cardiometabolic drugs to around $15 billion by the mid-2030s, up from a previous guidance of $10 billion. 
    Davis noted that Merck views Keytruda’s patent expiration as a “hill, not a cliff,” and is focused on making “the dip as small as possible and the return to growth as fast as possible.”

    Source: Merck

    Meanwhile, JPMorgan’s Schott said shares of Bristol Myers Squibb had a challenging 2023, as new drugs ramped up “slower than expected.”
    But JPMorgan expects those new products, along with the drugmaker’s recent acquisitions and growing mid- to late-stage pipeline, will “ultimately position the company for growth” after upcoming patent expirations. For example, Bristol Myers Squibb acquired Karuna Therapeutics, which develops drugs for psychiatric and neurological conditions, for $14 billion in December.
    Meanwhile, Schott said he believes J&J is “well positioned for healthy growth” after Stelara’s patent expires. The firm believes the company’s pharmaceutical business can deliver mid-single digit sales growth through 2030, he wrote in a December note.
    J&J’s medical devices business is also becoming a bigger share of the company’s revenue, which could help the company offset the Stelara patent cliff, CFRA analyst Sel Hardy said. The business raked in roughly $30 billion of J&J’s total $85 billion in 2023 sales. 
    In addition to internal developments, companies will likely look for opportunities to acquire more drugs, particularly those in late-stage development that are close to entering the market, said Arda Ural, EY’s Americas industry markets leader in health sciences and wellness.
    The biotech and pharmaceutical industry is also starting the year off with about $1.4 trillion on hand to make deals, he added.

    Drugmakers buy more time

    To avoid losing revenue, pharmaceutical companies are also moving to delay competition or extend patent protections on drugs. 
    Merck is testing a new, more convenient version of Keytruda that can be injected under the skin rather than through intravenous infusion. If that new form is approved, it may land the company a separate patent and extend Keytruda’s market exclusivity by several years. 
    Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient’s veins. A version that’s injected under the skin showed promising results in a late-stage trial in October, and could also lead to extended market exclusivity.

    Boxes of Opdivo from Bristol Myers are seen at the Huntsman Cancer Institute at the University of Utah in Salt Lake City, Utah, July 22, 2022.
    George Frey | Reuters

    J&J’s strategy with Stelara is a bit different.
    In 2022, J&J sued Amgen over its plan to market a biosimilar for Stelara, saying it would infringe two patents for the drug. J&J confidentially settled that lawsuit in May, but will allow Amgen to sell its biosimilar of Stelara no later than 2025. 
    A month later, J&J reached similar settlements with Alvotech and Teva Pharmaceuticals, which are also planning to launch a biosimilar of Stelara. 
    “Pharma is doing what they can to make sure that they squeezed that the most they can out of these drugs before they open up widely,” Mike Perrone, Baird’s biotech specialist, told CNBC. But he noted that “while you can tack on some years and extend revenues, there’s only so much time you can add.” 

    Medicare drug price negotiations are a factor

    Medicare drug price negotiations under the Inflation Reduction Act are an additional threat to companies, but how the policy affects revenues could differ depending on when a drug loses exclusivity. 
    Medicare is beginning price talks for the first round of 10 prescription medications this year. The talks include Stelara and Eliquis, along with a few other treatments facing patent expirations. 
    By the fall, the federal government will publish the agreed-upon prices for those medications, which will go into effect in 2026. 
    It’s too early to know how much Medicare will be able to negotiate down prices. 

    Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC.
    Anna Moneymaker | Getty Images

    But some experts said lower prices in 2026 may have less of an effect on drugs already expected to see revenue decline as patents expire around the same time. For example, Stelara will lose exclusivity in the U.S. in 2025. 
    It’s a slightly different story for drugs that will face generic competition after 202https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/what-are-biologics-questions-and-answers. Perrone said a lower negotiated price on a drug will result in companies losing revenue earlier, before the patents expire. 
    Still, he said the bigger threat to revenue for drugs – regardless of when they lose exclusivity – is competitors entering the market, not a new negotiated price with Medicare. More

  • in

    Your pay is still going up too fast

    Central bankers are entering the final stretch of their quest to defeat inflation. Rich-world prices are rising by 5.4% year on year, down from a peak of 10.7% in October 2022. Although it is impressive progress, the last part of the quest—getting inflation from 5.4% to central banks’ targets of around 2%—could be the hardest. That is because labour markets are not co-operating.image: The EconomistNot long ago employers wanted to hire many more workers than they could find, resulting in an unprecedented surge in unfilled vacancies (see chart 1). In 2022-23 global Google searches related to “labour shortage” jumped to their highest ever level. With plenty of other options, workers asked their bosses for big pay rises. Year-on-year wage growth across the rich world doubled from its pre-covid rate to close to 5% (see chart 2), adding to companies’ costs and in turn encouraging them to raise the prices they charged consumers.image: The EconomistTo get inflation under control, wage growth therefore had to come back down. Given weak productivity growth across the world, a 2% inflation target is probably achievable only if nominal wages grow by 3% a year or less. Central bankers hoped that by raising interest rates they would cause demand for labour to fall—ideally bringing down wage inflation without wrecking people’s livelihoods.The first part of the plan has worked. Demand for labour (ie, filled jobs plus unfilled vacancies) is now only 0.4% higher than the supply of workers in the rich world, down from a peak of 1.6%. Searches for “labour shortage” have fallen by a third. Almost everywhere you are now less likely to see “help wanted” signs.Lower demand for labour has also caused surprisingly little damage to people’s employment prospects. We estimate that, in the past year, falling vacancies have accounted for the entire decline in labour demand across the rich world. Over the same period the number of people actually in work has grown. The unemployment rate across the rich world remains below 5%. Some countries are even beating records. In Italy the share of working-age people in a job recently hit an all-time high—the country has swapped la dolce vita for la laboriosa vita.But despite falling labour demand, there is less evidence of the final part of the plan: lower wage inflation. Although American pay growth is down from more than 5.5% year on year to around 4.5%, that is probably still too high for the Federal Reserve’s 2% inflation target. And elsewhere there is little evidence of progress. In recent quarters wage growth across the rich world has hovered at around 5% year on year. British wage growth is more than 6%. “Very early indications for January show negotiated pay deals slowing only modestly,” reported analysts at JPMorgan Chase, a bank, last week. Euro-area pay is growing similarly fast.Is high wage growth, and thus above-target inflation, now baked into the economic cake? Some evidence suggests it is—especially in Europe. Spanish workers, for instance, have used their extra bargaining power to change their contracts, such that the share of workers whose pay is indexed to the inflation rate has risen from 16% in 2014-21 to 45% last year. A recent study by the OECD, a club of mostly rich countries, on Belgium worries about “more persistent inflation due to wage indexation”.More generous wage agreements today could lead to higher inflation tomorrow, leading in turn to even more generous wage agreements. Across the rich world strikes have become much more common, as workers seek higher wages. Last year America lost almost 17m working days to stoppages, more than in the previous ten years combined. Britain has also seen a surge in industrial action. On January 30th Aslef, a union for train drivers, is expected to begin a series of walkouts. Germany’s train drivers began their own strike on January 24th.There is, however, a more optimistic interpretation of these developments. Just as in 2021-22, when wages took a while to accelerate after labour demand rose, so today they could take time to lose speed. After all, companies and workers renegotiate wages infrequently—often annually—meaning that workers may only slowly realise that they have less bargaining power than before. Estimates for America published by Goldman Sachs, another bank, indicate that it can take a year or so for declines in labour demand to show up as lower wage growth—suggesting that the final stretch of disinflation will be annoyingly slow, but will pass. ■ More

  • in

    Stock market to ‘nowhere?’ Two ETF experts see more trouble ahead in China

    China may have trouble attracting investors again this year.
    ETF Action’s Mike Akins sees challenges tied to the country’s ability to generate stock market returns.

    “It’s kind of the old cliché. Fool me once, shame on you. Fool me twice, shame on me,” the firm’s founding partner told CNBC’s ETF Edge this week. “You’ve got this situation where China’s economy expanded. The stock market went nowhere. It’s been very volatile. There’s been periods where it’s gone way up but also come way down.”
    According to Atkins, emerging market ex-China products are among the largest inflows ETF Action is seeing.
    “You’ve got a whole new issue that you have to think about when going to that market,” he said. “Is it investible from a standpoint of total return? Or is it really a growth story in the economy alone and not in the actual return of the stock market?”
    Franklin Templeton Investments’ David Mann cites another issue for investor hesitancy.
    “The geopolitical factor with China is certainly on everyone’s mind,” said Mann, the firm’s global head of product and capital markets. “China was down last year. It is down again this year. Investors are probably looking a lot at the political side.”
    The Hang Seng Index is down more than 6% this year and almost 30% over the past 52 weeks.

    Disclaimer More